1231 2020 Approvals review
BioCentury & Getty Images


Another year of firsts in FDA’s new drug approvals

Targeted therapies beat out immuno-oncology, new modalities in 2020’s crop of new drug approvals

The pandemic didn’t slow drug approvals in the U.S., but the market is still waiting for new modalities and the next wave of immuno-oncology therapies.

Jan 1, 2021 | 2:57 AM GMT

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and new drug constructs.

FDA’s Center for Drug Evaluation

Read the full 991 word article

How to gain access

Continue reading with a
two-week free trial.